Proteins linked to longevity also linked to Alzheimer's

Jul 27, 2010 by Anne Trafton
Biology professor Leonard Guarente. Photo: Donna Coveney

Over the past 20 years, scientists have learned that proteins called sirtuins play a vital role in longevity and stress response in organisms as diverse as humans, yeast and mice. A new paper from MIT biologists now reveals a surprising additional role for sirtuins: They appear to suppress the production of amyloid beta proteins, which form plaques in the brains of Alzheimer’s patients.

The finding, reported in the July 23 issue of Cell, suggests that targeting sirtuins could offer a promising new approach to treating Alzheimer’s, says Professor Leonard Guarente, leader of the research team.

Guarente and his colleagues showed that boosting the activity of a sirtuin called SIRT1 stifled the production of amyloid beta proteins and enhanced in mice engineered to express Alzheimer’s symptoms. This marks the first time sirtuins have been linked to those proteins.

Several drug companies are now developing and testing compounds that enhance sirtuin activity. Guarente, who consults for one of those companies, Sirtris (a unit of GlaxoSmithKline), believes that sirtuin activators may eventually prove useful against Alzheimer’s, which affects up to one-third of people who reach age 80.

Protein clumping

Though are a defining feature of Alzheimer’s disease, many researchers now believe that the symptoms are caused by smaller clumps of two or three amyloid beta (A-beta) fragments, not the larger plaques.

A-beta peptides form when proteins called amyloid precursor proteins (APPs) are broken into smaller pieces. However, APPs can also be cleaved at other sites, producing harmless protein fragments. APP’s normal function is unknown, but it has been established that people with a that stimulates overproduction of APP are more likely to develop Alzheimer’s at an early age (before age 65).

Another mutation that stimulates early-onset Alzheimer’s (which accounts for 5 to 10 percent of cases) occurs in the gene for the enzyme that cleaves APP into A-beta peptides. Although those genes for early-onset Alzheimer’s have been identified, “with late-onset Alzheimer’s, we still don’t know why some people get it and other people don’t,” says Guarente.

Guarente, who first discovered the life-extending ability of sirtuins 20 years ago, started studying their role in Alzheimer’s after some recent studies showed that the gene that produces sirtuins, SIRT1, appears to protect mice from the effects of Alzheimer’s disease. When those studies came out, “I thought that the mice with extra SIRT1 probably had just as much A-beta, but that SIRT1 was protecting them against it,” Guarente recalls. “It turns out that they were actually making less A-beta peptide.”

In the Cell paper, Guarente and his colleagues showed that SIRT1 activates the production of an enzyme (alpha-secretase) that carves APPs into harmless fragments, preventing the formation of Alzheimer’s-associated amyloid peptides. Mice engineered to produce excess sirtuins had reduced peptide levels, while mice with SIRT1 knocked out showed elevated peptide levels.

Furthermore, learning and memory deficits in the Alzheimer’s mice were improved when SIRT1 was overproduced and worsened when the gene was deleted. The researchers also found that SIRT1 activates the so-called notch-signaling pathway via the elevated levels of alpha-secretase, which protects neurons and helps maintain brain function.

A new target for Alzheimer’s

The research, funded by the American Parkinson Disease Association, National Institutes of Health and the Paul F. Glenn Foundation, demonstrates that drugs that activate SIRT1 in the brain may be a promising approach to treating Alzheimer’s, says Guarente. Any such drug would have to be able to cross the blood-brain barrier, which prevents large molecules from diffusing into the brain.

Sirtris, a company co-founded by Guarente and then bought by , is now testing SIRT1 activators in a clinical trial for diabetes. Guarente believes that related drugs could have an impact on a range of neurodegenerative diseases, as well as diabetes and other diseases of aging.

However, any potential drug for Alzheimer’s would likely take several years to reach clinical trials, because of the need to find a drug that crosses the blood-brain barrier, says Guarente.

Rudolph Tanzi, professor of neurology at Harvard Medical School, says the new findings also suggest another approach: targeting one specific aspect of SIRT1’s activity. Tanzi’s lab recently found that mutations in the gene that produces alpha-secretase (ADAM10) are associated with late-onset Alzheimer’s disease.

“If this is how SIRT1 protects against Alzheimer’s -- by turning on ADAM10 -- you could try finding a drug that specifically addresses that mechanism,” instead of globally activating SIRT1, says Tanzi. 

Explore further: Newly discovered gut virus lives in half the world's population

Related Stories

Gene linked to aging also linked to Alzheimer's

Jul 22, 2010

MIT biologists report that they have discovered the first link between the amyloid plaques that form in the brains of Alzheimer's patients and a gene previously implicated in the aging process, SIRT1.

Researchers link gene to cholesterol

Oct 11, 2007

MIT researchers have discovered a link between a gene believed to promote long lifespan and a pathway that flushes cholesterol from the body.

Alzheimer's prevention role discovered for prions

Jul 03, 2007

A role for prion proteins, the much debated agents of mad cow disease and vCJD, has been identified. It appears that the normal prions produced by the body help to prevent the plaques that build up in the brain to cause Alzheimer’s ...

Alzheimer's enzyme acts as a tumor suppressor

Jun 08, 2007

Researchers at Burnham Institute for Medical Research have provided the first evidence that gamma-secretase, an enzyme key to the progression of Alzheimer’s, acts as a tumor suppressor by altering the pathway of epidermal ...

Recommended for you

Monitoring the rise and fall of the microbiome

3 hours ago

Trillions of bacteria live in each person's digestive tract. Scientists believe that some of these bacteria help digest food and stave off harmful infections, but their role in human health is not well understood.

Antioxidant biomaterial promotes healing

11 hours ago

When a foreign material like a medical device or surgical implant is put inside the human body, the body always responds. According to Northwestern University's Guillermo Ameer, most of the time, that response can be negative ...

Immune response may cause harm in brain injuries, disorders

13 hours ago

Could the body's own immune system play a role in memory impairment and cognitive dysfunction associated with conditions like chronic epilepsy, Alzheimer's dementia and concussions? Cleveland Clinic researchers believe so, ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

baudrunner
not rated yet Jul 27, 2010
I think that peptides, which are ubiquitous throughout the body, serve as the raw materials for the manufacture of proteins. They are drawn into the cells when needed and processed so that protein synthesis can occur. Where else do those amino acids come from? Peptides aren't excess or waste material. There is no difference between neural peptides and intestinal peptides, or any other peptides found anywhere else in the body, because they are just amino acid chains waiting to be used up. Those amino acids come from our diet. Better that they be organized into chains then float about independently, which would needlessly complicate the process of gathering them for use.